48例鲍曼不动杆菌下呼吸道感染耐药性及治疗分析  

作　　者：张黎[1] 钱效森[1] 刘远程[1] 

机构地区：[1]北京民航总医院呼吸内科,100123

出　　处：《当代医学》2012年第26期140-141,共2页Contemporary Medicine

摘　　要：目的监测医院2年内鲍曼不动杆菌下呼吸道感染的耐药现状,并总结鲍曼不动杆菌下呼吸道感染的治疗心得。方法对呼吸内科2009年6月～2011年5月收治的48例鲍曼不动杆菌下呼吸道感染患者,回顾性分析其细菌学特点、抗菌药物选择及疗效。结果48例中26例接受以碳青霉烯类为主治疗,16例(61.54%)获得临床改善或治愈;另22例接受以头孢哌酮/舒巴坦为主治疗,15例(68.18%)获得临床改善或治愈。结论为获得更好的疗效,延缓耐药性的产生,治疗鲍曼不动杆菌下呼吸道感染时,应加强药敏试验,依据药敏结果合理选用抗菌药物,重症时联合用药。Objective To investigate the drug resistance of lower respiratory infection caused by Acinetobacter baumannii in two years,and summary treatment experience.Methods By a retrospective study,a total of 48 lower respiratory infection caused by Acinetobacter baumannii were collected from June 2009 to May 2011,retrospectively analyze the bacteriological characteristics,choice of antibiotics and therapeutic effect in clinic.Results Sixteen out of 26 patients who received a carbapenem-based treatment had successful clinical outcome,the total effective rate was 61.53%.Fifteen out of 22 patients who received a cefoperazone/sulbactam-based treatment had successful clinical outcome,the total effective rate was 68.18%.Conclusion Susceptibility testing should be strengthened,and rational use of antibiotics based on susceptibility results,which can effectively treat the infection caused by Acinetobacter baumannii and slow down development of drug resistance.The clinical therapeutic effect of combination therapy is encouraging.

关 键 词：鲍曼不动杆菌 下呼吸道感染 耐药性 临床疗效 

分 类 号：R446.5[医药卫生—诊断学]